ABSTRACT
On 7 July 2002, shocking and striking news spread throughout the world, following the Women’s Health Initiative (WHI) Investigators’ report1 that hormone replacement therapy (HRT) using conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day (continuous combined method) could not prevent primary coronary heart disease (CHD), and the clinical trial was stopped. More recently, on 8 January 2003, the US Food and Drug Administration (FDA)2 limited indications for general use of HRT to climacteric syndrome only. However, the Cache County Study3 recommended HRT use after the menopause to prevent Alzheimer’s disease (AD). This chapter discusses HRT in relation to AD.
